Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

Part of paid clinical trials in Naples, Florida.

Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Study ID
NCT07226726
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Congenital Myasthenic Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AlloEx exosomes — BIOLOGICAL
    This is an intranasal treatment of exosomes derived from mesenchymal stem cells.

Study Details

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Key Dates

Start date
Jan 1, 2025
Status verified
Nov 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group

Primary Outcome Measure

Oxygen Saturation [ Time Frame: From enrollment to 6 months after treatment ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Prodromos Stem Cell InstituteNaplesFlorida34102
Chadwick Prodromos, MD
[email protected]
847-699-6810
Prodromos Stem Cell InstituteIrvingTexas75039
Chadwick Prodromos, MD
[email protected]
847-699-6810

Find similar trials in Naples, FL

By research site
Prodromos Stem Cell Institute· Naples, FLProdromos Stem Cell Institute· Irving, TX

Related Studies